0000899243-23-014879.txt : 20230608
0000899243-23-014879.hdr.sgml : 20230608
20230608163158
ACCESSION NUMBER: 0000899243-23-014879
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230606
FILED AS OF DATE: 20230608
DATE AS OF CHANGE: 20230608
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kollins John A
CENTRAL INDEX KEY: 0001391070
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39041
FILM NUMBER: 231002383
MAIL ADDRESS:
STREET 1: SATSUMA PHARMACEUTICALS, INC.
STREET 2: 400 OYSTER POINT BOULEVARD, SUITE 221
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Satsuma Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001692830
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 813039831
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4819 EMPEROR BOULEVARD
STREET 2: SUITE 340
CITY: DURHAM
STATE: NC
ZIP: 27703
BUSINESS PHONE: 415-505-0809
MAIL ADDRESS:
STREET 1: 4819 EMPEROR BOULEVARD
STREET 2: SUITE 340
CITY: DURHAM
STATE: NC
ZIP: 27703
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-06-06
1
0001692830
Satsuma Pharmaceuticals, Inc.
STSA
0001391070
Kollins John A
C/O SATSUMA PHARMACEUTICALS, INC.
400 OYSTER POINT BOULEVARD, SUITE 221
SOUTH SAN FRANCISCO
CA
94080
1
1
0
0
President and CEO
0
Common Stock, $0.0001 par value
2023-06-06
4
U
0
305911
0.91
D
0
D
Stock Option (right to buy)
29.00
2023-06-08
4
D
0
175000
0.00
D
Common Stock
175000
0
D
Stock Option (right to buy)
4.60
2023-06-08
4
D
0
240000
0.00
D
Common Stock
240000
0
D
Stock Option (right to buy)
3.46
2023-06-08
4
D
0
505000
0.00
D
Common Stock
505000
0
D
Stock Option (right to buy)
4.56
2023-06-08
4
D
0
276595
0.00
D
Common Stock
276595
0
D
Stock Option (right to buy)
1.04
2023-06-08
4
D
0
127659
0.00
D
Common Stock
127659
0
D
Stock Option (right to buy)
0.90
2023-06-08
4
D
0
127659
D
Common Stock
127659
0
D
Stock Option (right to buy)
0.90
2023-06-08
4
D
0
127659
D
Common Stock
127659
0
D
Disposed of to SNBL23 Merger Sub, Inc. ("Merger Sub"), which, pursuant to the Agreement and Plan of Merger, dated April 16, 2023, by and between the Issuer, Shin Nippon Biomedical Laboratories, Ltd., a Japanese corporation ("Parent"), and Merger Sub (the "Merger Agreement"), commenced a tender offer to acquire any and all of the outstanding shares of the Issuer's common stock at a purchase price of $0.91 per share and one non-transferable contractual contingent value right (the "Offer Price").
Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer with an exercise price that is less than the $0.91 that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than $0.91 and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.
/s/ Thomas P. O'Neil as Attorney in Fact for John A. Kollins
2023-06-08